» Articles » PMID: 28567547

Breast MR Imaging for the Assessment of Residual Disease Following Initial Surgery for Breast Cancer with Positive Margins

Overview
Journal Eur Radiol
Specialty Radiology
Date 2017 Jun 2
PMID 28567547
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To determine the accuracy of post-operative MR in predicting residual disease in women with positive margins, emphasizing the size thresholds at which residual disease can be confidently identified.

Methods: This IRB-approved HIPAA-compliant retrospective study included 175 patients with MR after positive margins following initial surgery for breast cancer. Two expert readers independently re-evaluated MR images for evidence of residual disease at the surgical cavity and multifocal/multicentric disease. All patients underwent definitive surgery and MR findings were correlated to histopathology.

Results: 139/175 (79.4%) patients had residual disease at surgery. Average overall sensitivity, specificity, PPV and NPV for residual disease at the surgical cavity were 73%, 72%, 91% and 45%, respectively. The readers identified 42/45 (93%, reader 1) and 43/45 (95%, reader 2) patients with residual invasive disease at the cavity of ≥5 mm and 22/22 (100%, both readers) patients with disease ≥10 mm. Average sensitivity, specificity, PPV and NPV for unknown multifocal/multicentric disease were 90%, 96%, 93% and 86%, respectively.

Conclusions: Post-operative breast MR can accurately depict ≥5-mm residual disease at the surgical cavity and unsuspected multifocal/multicentric disease. These findings have the potential to lead to more appropriate selection of second surgical procedures in women with positive margins.

Key Points: • Post-operative breast MRI accurately defines residual disease of ≥5 mm. • Surgical cavity sensitivities were high for both invasive carcinoma and DCIS. • Post-surgical changes and very small residual disease (<5 mm) may overlap. • Post-operative breast MRI may help planning an accurate re-resection.

Citing Articles

Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model.

Tong Y, Hu Z, Wang H, Huang J, Zhan Y, Chai W Eur Radiol. 2024; 34(8):5477-5486.

PMID: 38329503 PMC: 11255056. DOI: 10.1007/s00330-024-10609-7.


Unlabeled aspirin as an activatable theranostic MRI agent for breast cancer.

Pavuluri K, Yang E, Ayyappan V, Sonkar K, Tan Z, Tressler C Theranostics. 2022; 12(4):1937-1951.

PMID: 35198081 PMC: 8825591. DOI: 10.7150/thno.53147.


Role of early post-operative breast MRI: how helpful is it in deciding the next step for women who may have residual disease?.

Healy N, Benson J, Sinnatamby R BJR Open. 2021; 3(1):20210024.

PMID: 34381952 PMC: 8327930. DOI: 10.1259/bjro.20210024.


Understanding indications and defining guidelines for breast magnetic resonance imaging.

Schoub P SA J Radiol. 2019; 22(2):1353.

PMID: 31754513 PMC: 6837823. DOI: 10.4102/sajr.v22i2.1353.

References
1.
Peterson M, Schultz D, Reynolds C, Solin L . Outcomes in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys. 1999; 43(5):1029-35. DOI: 10.1016/s0360-3016(98)00519-7. View

2.
Frei K, Kinkel K, Bonel H, Lu Y, Esserman L, Hylton N . MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. AJR Am J Roentgenol. 2000; 175(6):1577-84. DOI: 10.2214/ajr.175.6.1751577. View

3.
Fisher B, Jeong J, Anderson S, Bryant J, Fisher E, Wolmark N . Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002; 347(8):567-75. DOI: 10.1056/NEJMoa020128. View

4.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A . Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002; 347(16):1227-32. DOI: 10.1056/NEJMoa020989. View

5.
Poggi M, Danforth D, Sciuto L, Smith S, Steinberg S, Liewehr D . Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003; 98(4):697-702. DOI: 10.1002/cncr.11580. View